SB1096, titled the Preserve Access to Affordable Generics and Biosimilars Act, would prohibit certain patent-settlement agreements between brand-name drug manufacturers and generic or biosimilar competitors when those agreements have anticompetitive effects. The bill targets so-called “reverse payment” or “pay-for-delay” settlements, where the brand-name company transfers value to a potential competitor in exchange for delaying market entry of a generic drug, biosimilar, or interchangeable biological product. It creates a new section of the Federal Trade Commission Act making such agreements an unfair method of competition, with a rebuttable presumption of illegality when a competitor receives something of value and agrees to delay research, development, manufacturing, marketing, or sales.
The bill also amends federal drug and antitrust-related statutes to strengthen disclosure and enforcement. It expands required FTC/DOJ reporting to cover biosimilar-related patent settlements, requires certifications that filed agreements are complete and include related oral or ancillary terms, clarifies that settlements of Patent Trial and Appeal Board proceedings are covered, and authorizes FTC civil litigation and penalties. It also provides that a violation can trigger forfeiture of the 180-day generic exclusivity period and directs the FTC to report within one year on whether an additional exception should be added for consideration involving releases or waivers of damages claims. The bill applies prospectively to agreements entered into on or after enactment and includes a severability clause.
The bill’s impact would be to change federal law governing pharmaceutical patent settlements by making it harder for branded drug and biologic companies to structure delayed-entry deals that preserve monopoly pricing. It would affect NDA holders, ANDA filers, biological product license holders, biosimilar applicants, and related affiliates, while giving the FTC a clearer enforcement role and additional remedies. In practical terms, the measure is intended to accelerate entry of lower-cost generics and biosimilars, which could reduce prescription drug spending for consumers, insurers, and federal health programs.
Overall sentiment in the available record appears strongly supportive and bipartisan, with the bill introduced by Senator Klobuchar and co-sponsored by Senators Grassley, Durbin, Cramer, Blumenthal, Ernst, Welch, Kelly, and Booker. The committee-reported version suggests the Judiciary Committee advanced the measure with at least some consensus, and there are no recorded votes or transcript excerpts showing organized opposition in the materials provided. The findings section reflects a policy view that reverse-payment settlements undermine competition and consumer savings, which appears to be the central rationale behind the bill.
The main point of contention is likely the scope of the prohibition and the presumption of anticompetitive effect. The bill would treat many settlements involving value transfers and delayed entry as presumptively unlawful unless the parties can prove either that the payment was solely for other goods or services or that procompetitive benefits outweigh anticompetitive harms. That structure could concern brand-name manufacturers and some generic or biosimilar firms that use patent settlements to resolve litigation, especially because the bill also reaches related agreements and ancillary terms. The FTC is also asked to study whether an additional exclusion should be created for certain consideration tied to releases or waivers of damages claims, indicating that this issue may remain open for further refinement.
SB1096 would amend the Federal Trade Commission Act, the Medicare Prescription Drug, Improvement, and Modernization Act reporting provisions, and the Federal Food, Drug, and Cosmetic Act to restrict and police patent settlements in the pharmaceutical sector. It would create a new federal prohibition on anticompetitive agreements that delay generic or biosimilar entry, authorize FTC enforcement and civil penalties, require broader disclosure and certification of settlement terms, and make violations relevant to forfeiture of the 180-day generic exclusivity period. The bill would primarily affect brand-name drug and biologic manufacturers, generic drug applicants, biosimilar applicants, and their patent-holding affiliates.
The available context suggests favorable sentiment, with bipartisan sponsorship and committee reporting indicating support for the bill’s consumer-pricing and competition goals. No recorded votes or hearing transcripts are provided, but the bill’s findings and structure reflect a clear anti-pay-for-delay policy consensus. The measure appears to have been advanced without visible public controversy in the supplied materials.
The principal contention is whether the bill goes too far in presuming that settlements involving value transfers and delayed entry are anticompetitive. Pharmaceutical companies may argue that some settlements resolve legitimate patent disputes and that payments can reflect lawful compensation for services, litigation costs, or other business arrangements. The bill attempts to address that concern through exceptions for compensation solely for other goods or services, reasonable litigation expenses, and covenants not to sue, and it directs the FTC to study whether an additional exclusion is needed for consideration tied to releases or waivers of damages claims. That indicates the balance between deterring pay-for-delay deals and preserving legitimate patent settlements is the main unresolved issue.